Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Aug 21, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Aug 21, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Monopar filed a routine 8-K, no major news.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on August 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by Monopar Therapeutics, without disclosing new material events or financial performance details.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that suggests an immediate change in risk for investors.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- August 21, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Monopar Therapeutics Inc.
In which state was Monopar Therapeutics incorporated?
Monopar Therapeutics was incorporated in Delaware.
What is the address of Monopar Therapeutics' principal executive offices?
The address of Monopar Therapeutics' principal executive offices is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the telephone number for Monopar Therapeutics?
The telephone number for Monopar Therapeutics, including area code, is (847) 388-0349.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2024-08-21 08:00:13
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240820_8k.htm (8-K) — 25KB
- ex_716956.htm (EX-99.1) — 10KB
- monologo.jpg (GRAPHIC) — 4KB
- p01.jpg (GRAPHIC) — 30KB
- p02.jpg (GRAPHIC) — 42KB
- 0001437749-24-027432.txt ( ) — 279KB
- mnpr-20240821.xsd (EX-101.SCH) — 3KB
- mnpr-20240821_def.xml (EX-101.DEF) — 12KB
- mnpr-20240821_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240821_pre.xml (EX-101.PRE) — 12KB
- mnpr20240820_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 21, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that Monopar has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated August 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: August 21, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer